StreetAlpha.app
Home › Stocks › VSTM

Verastem, Inc. (VSTM)

Healthcare
$6.33
▼ −7.73%
LAST CLOSE · NOV 20

Verastem develops and markets cancer medicines that target the RAS/MAPK pathway, including an approved ovarian cancer treatment. It last closed at $6.33 on Nov 20, down 7.73% on the day. The next earnings report for VSTM is expected around Wed, Feb 3, 2027. For the quarter ended Sep 2026, VSTM reported EPS of -$0.74 on revenue of $24.0M, with revenue up 113.6% from a year ago. Over its last 8 reports the stock moved an average of 9.9% the session after earnings. Over the last 12 months VSTM insiders bought $0 of stock on the open market and sold $1.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is VSTM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VSTM.

Key Stats

Last 12 months
Results
Revenue
$100.3M
Net income
−$178.9M
−178.4% margin
EPS (diluted)
−$1.84
Operating margin
−193.7%
−$194.3M operating income
Valuation
Market cap
$797.7M
126.0M shares
P/E
–
No P/E while losing money
Price to sales
8.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$172.8M
At Sep 30
Shareholder equity
$10.1M
Shares outstanding
126.0M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.1M$2.1MFY2021FY2022: $2.6M$2.6MFY2022FY2024: $10.0M$10.0MFY2024FY2025: $30.9M$30.9MFY2025

From VSTM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 3
Estimated date · Time not announced
Reported EPS
-$0.74
Quarter ended Sep 2026
Year ago EPS
-$1.35
Same quarter last year
Revenue
$24.0M
+113.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.55Dec '24Mar 2025: -$0.96Mar '25Jun 2025: -$0.62Jun '25Sep 2025: -$1.35Sep '25Dec 2025: -$0.29Dec '25Mar 2026: -$0.46Mar '26Jun 2026: -$0.35Jun '26Sep 2026: -$0.74Sep '26Latest -$0.74
Revenue by quarter
Dec 2024: $0Dec '24Jun 2025: $2.1MJun '25Sep 2025: $11.2MSep '25Dec 2025: $17.5MDec '25Mar 2026: $18.7MMar '26Jun 2026: $40.1MJun '26Sep 2026: $24.0MSep '26Latest $24.0M
How VSTM moved after its last 8 reports
Average move the session after a report ±9.9%
Oct 14, 2026Time not announced+3.5%
Aug 6, 2026After the close+14.0%
Feb 4, 2026Time not announced+7.8%
Nov 4, 2025Time not announced−20.1%
Jan 13, 2025Time not announced−6.8%
Feb 2, 2023Time not announced+8.7%
Aug 8, 2022Time not announced+7.6%
Mar 28, 2022Time not announced+10.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VSTMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VSTM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VSTM

Technical Analysis

VSTM · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, oversold

The stock is 38% below its 20 day and 33% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is weak (RSI 28), oversold. The nearest support is the 200 day average at $6.31, and the nearest resistance the swing high (Jul 27) at $6.46.

Short trendBearish
Long trendBullish
MomentumWeak
StretchOversold
VolatilityHigh, 10.0%/day
Key levels
$10.8252 week high+70.9%
$8.7320 day average+37.9%
$8.4150 day average+32.9%
$7.44100 day average+17.5%
$6.68Pivot R1+5.5%
$6.47Pivot+2.2%
$6.46Swing high (Jul 27)+2.1%
$6.33Last close
$6.31200 day average−0.3%
$6.12Pivot S1−3.3%
$5.54Swing low (Jul 31)−12.5%
$3.4352 week low−45.8%
Indicators
RSI (14)27.65Oversold below 30Oversold
MACD-0.50Below its signal lineBearish
Stochastic2.4Near the bottom of its rangeOversold
ADX (14)33.3Trending down
Williams %R-97.9Oversold below −80, overbought above −20Oversold
CCI (20)-165.2Oversold below −100, overbought above 100Oversold
Rate of change−24.7%Change over 10 sessionsBearish
ATR (14)$0.64Typical daily range, 10.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for VSTM

What happened before

See how VSTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VSTM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VSTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2012.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VSTMHow many large options trades hit VSTM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

VSTM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲94 buying vs 73 selling
  • ▼Held by funds -8.3 pts
  • ▲Funds holding +4
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162158+2.5%
In funds' top 1052+150.0%
Held by funds70.1%78.5%−8.3 pts
New / increased35 / 5933 / 69−7.8%
Reduced / sold out44 / 2935 / 28+15.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VSTM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VSTM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.1M22 sales · 6 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $239K2026-01 sold $110K2026-02 sold $6K2026-05 sold $5K2026-06 sold $104K2026-08 sold $8K2026-09 sold $4242026-10 sold $373K2026-11 sold $12KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 3Dan PatersonPresident and CEOSale plan1,299$9.60$12K
Oct 1Daniel CalkinsCFOSale plan2,566$8.00$21K
Oct 1Dan PatersonPresident and CEOSale plan44,121$8.00$353K
Sep 21Daniel CalkinsCFOSale plan55$7.70$424
Aug 3Dan PatersonPresident and CEOSale plan1,302$5.81$8K
Jun 22Daniel CalkinsCFOSale plan4,089$4.18$17K
Every insider buy and sale for VSTM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VSTM insider trades →

From SEC Form 4 filings by VSTM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VSTM is in one of them and how their past VSTM trades turned out.

VSTM in the AI portfolios
Loading…

VSTM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VSTM in an article yet. Here's the latest on the wider market.

VSTM in the news

About Verastem

Verastem is a biopharmaceutical company based in Needham, Massachusetts, that develops and sells medicines for cancers driven by the RAS/MAPK pathway. Its approved product, AVMAPKI FAKZYNJA CO-PACK, is marketed in the United States to adults with recurrent low grade serous ovarian cancer that has KRAS mutations and who have had prior systemic therapy. Its pipeline includes VS-7375, an oral KRAS G12D inhibitor being studied in pancreatic, lung and colorectal cancers. Its customers are cancer patients and the physicians who treat them.

Headquarters
Needham, MA